Cancer Patients May Be Treated With Drugs That Provide No Benefit
Many cancer patients may be treated with drugs that were granted accelerated approval but do not provide a clinical benefit, a study suggests.
Diagnosis & Disease Information
Frontline Pembrolizumab Improves PFS, OS in HER2- Gastric/GEJ Cancers
Adding pembrolizumab to frontline chemotherapy improves outcomes in patients with HER2-negative, advanced gastric or GEJ cancers, a phase 3 trial suggests.
Esophageal, Gastric Cancer Risks Reduced With Bariatric Surgery for Obesity
The use of bariatric surgery in patients with severe obesity is associated with a reduced incidence of esophageal and gastric cancers.
Full Year of Adjuvant S-1 Chemo “Highly Recommended” for Stage II Gastric Cancer
Long-term results confirm that 4 courses of S-1 chemotherapy is inferior to the standard 8 courses in patients with stage II gastric cancer.
Procedural Volume May Impact Outcomes of Endoscopic Submucosal Dissection
Patients with gastric cancer or dysplasia who underwent endoscopic submucosal dissection at very low-volume centers had a higher risk of adverse outcomes.
Regorafenib May Be New Option for Advanced, Refractory Gastric/GEJ Cancer
Combining regorafenib with best supportive care improves outcomes in advanced, refractory gastric/GEJ cancer, a phase 3 study suggests.
Frontline Tislelizumab Improves Survival in PD-L1+, Advanced Gastric/GEJ cancer
Tislelizumab plus chemotherapy may be a new first-line treatment option for patients with PD-L1-positive, advanced gastric or GEJ cancer.
HER-Vaxx Improves Survival in HER2+ Advanced Gastric/GEJ Cancer
Adding HER-Vaxx to standard chemotherapy improves survival in patients with HER2-overexpressing, advanced gastric or GEJ cancer, a study suggests.
Frontline Zolbetuximab Plus Chemo May Be New Standard Care for Gastric/GEJ Cancer
Adding zolbetuximab to standard frontline chemotherapy can improve outcomes in certain patients with gastric/GEJ cancer, a phase 3 study suggests.
COVID-Related Delays in Gastrointestinal Cancer Diagnosis Did Not Impact Survival
The COVID-19 pandemic delayed the diagnosis of gastric, esophageal, or GEJ cancer but did not impact survival in a single-center study.
- Loading...
Loading...
Next post in ASCO GI 2023
Loading... 
Loading...